Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
104.54 141.24 194.03 270.25 366.26 670.53 801.54 632.36 634.44 738.26
Revenue Growth
25.14% 35.10% 37.38% 39.28% 35.53% 83.08% 19.54% (21.11%) 0.33% 16.36%
Gross Profit
57.42 74.19 107.50 151.15 209.63 391.25 455.71 278.44 274.65 386.25
Operating Income
15.97 14.01 25.99 36.08 69.82 167.25 224.67 47.70 (35.11) 55.17
EBT
11.69 7.25 21.44 26.15 59.22 153.54 219.14 56.71 (27.03) 62.38
Income after Tax
11.68 28.35 16.62 21.41 59.93 128.29 185.96 35.60 (25.51) 48.89
Net Income Common
11.68 28.35 16.62 21.41 59.93 128.29 185.96 35.60 (25.51) 48.89
EPS (Diluted)
0.34 0.72 0.37 0.44 1.11 2.24 3.24 0.74 (0.46) 0.86
Shares (Diluted, Weighted)
34.10 39.15 45.47 49.21 53.89 57.26 57.46 56.38 55.94 56.56
Gross Margin
54.93% 52.53% 55.40% 55.93% 57.23% 58.35% 56.85% 44.03% 43.29% 52.32%
EBIT Margin
15.28% 9.92% 13.39% 13.35% 19.06% 24.94% 28.03% 7.54% (5.53%) 7.47%
Net Profit Margin
11.17% 20.07% 8.56% 7.92% 16.36% 19.13% 23.20% 5.63% (4.02%) 6.62%
Free Cash Flow Margin
3.10% 8.49% 9.65% 16.30% 9.91% 7.12% 4.83% 11.85% 22.46% 12.45%
EBITDA
21.31 24.51 46.01 64.49 107.86 217.23 277.47 118.71 50.15 150.56
EBIT
15.97 14.01 25.99 36.08 69.82 167.25 224.67 47.70 (35.11) 55.17

Show all line items

In millions of $ except per-share values · columns are period end dates